{"title":"Impact of COVID-19 pandemic on unresectable pancreatic cancer: a regional cohort study in Japan.","authors":"Rei Suzuki, Hiroyuki Asama, Naoki Konno, Ko Watanabe, Hiromichi Imaizumi, Yuichi Waragai, Mitsuru Sugimoto, Yuki Sato, Hiroki Irie, Hiroshi Shimizu, Kentaro Sato, Tadayuki Takagi, Hiromasa Ohira","doi":"10.5387/fms.24-00011","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic has had a significant impact on healthcare, including cancer management. This study aimed to investigate the prognostic impact of the COVID-19 pandemic, throughout its duration, on patient care for pancreatic ductal adenocarcinoma (PDAC).</p><p><strong>Methods: </strong>We collected clinical data of patients with unresectable PDAC who underwent palliative chemotherapy at five medical facilities in Fukushima, Japan. The patients were divided into two groups: group A (nonpandemic cohort) and group B (pandemic cohort). Survival analysis was performed for progression-free survival (PFS) and overall survival (OS) via the Kaplan‒Meier method with the log-rank test.</p><p><strong>Results: </strong>In total, 249 patients were selected for the analysis. Patients in Group B had significantly greater serum CA19-9 levels and proportions of patients selected for combination therapy; however, we did not find significant differences between the two groups in PFS (Group A vs. Group B: 5.6 months vs. 4.4 months, HR = 0.82 (95% CI, 0.6-1.1), p = 0.17) or OS (14.8 months vs. 12.3 months, HR = 0.81 (95% CI, 0.7-1.3), p = 0.81) in the survival analysis.</p><p><strong>Conclusions: </strong>We did not observe a negative impact on the prognosis of patients with unresectable PDAC throughout the COVID-19 pandemic.</p>","PeriodicalId":44831,"journal":{"name":"Fukushima Journal of Medical Science","volume":" ","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fukushima Journal of Medical Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5387/fms.24-00011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The COVID-19 pandemic has had a significant impact on healthcare, including cancer management. This study aimed to investigate the prognostic impact of the COVID-19 pandemic, throughout its duration, on patient care for pancreatic ductal adenocarcinoma (PDAC).
Methods: We collected clinical data of patients with unresectable PDAC who underwent palliative chemotherapy at five medical facilities in Fukushima, Japan. The patients were divided into two groups: group A (nonpandemic cohort) and group B (pandemic cohort). Survival analysis was performed for progression-free survival (PFS) and overall survival (OS) via the Kaplan‒Meier method with the log-rank test.
Results: In total, 249 patients were selected for the analysis. Patients in Group B had significantly greater serum CA19-9 levels and proportions of patients selected for combination therapy; however, we did not find significant differences between the two groups in PFS (Group A vs. Group B: 5.6 months vs. 4.4 months, HR = 0.82 (95% CI, 0.6-1.1), p = 0.17) or OS (14.8 months vs. 12.3 months, HR = 0.81 (95% CI, 0.7-1.3), p = 0.81) in the survival analysis.
Conclusions: We did not observe a negative impact on the prognosis of patients with unresectable PDAC throughout the COVID-19 pandemic.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
